Maxcyte Stock Today
| MXCT Stock | USD 3.61 0.06 1.69% |
Performance0 of 100
| Odds Of DistressLess than 20
|
MaxCyte is selling for under 3.61 as of the 25th of November 2024; that is 1.69 percent increase since the beginning of the trading day. The stock's last reported lowest price was 3.52. MaxCyte has about a 20 % chance of experiencing some form of financial distress in the next two years of operation but has generated negative returns over the last 90 days. Equity ratings for MaxCyte are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 26th of October 2024 and ending today, the 25th of November 2024. Click here to learn more.
Business Domain Health Care Equipment & Services | IPO Date 30th of July 2021 | Category Healthcare | Classification Health Care |
MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. The company was incorporated in 1998 and is headquartered in Rockville, Maryland. Maxcyte operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. The company has 105.48 M outstanding shares of which 3.24 M shares are now shorted by private and institutional investors with about 11.38 trading days to cover. More on MaxCyte
Moving together with MaxCyte Stock
| 0.86 | AGL | agilon health Buyout Trend | PairCorr |
Moving against MaxCyte Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
MaxCyte Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO, President | Maher Masoud | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Health Care Equipment & Supplies, Health Care Equipment & Services, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, Health Care, Health Care Equipment & Supplies, Medical Devices, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsMaxCyte can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand MaxCyte's financial leverage. It provides some insight into what part of MaxCyte's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
MaxCyte (MXCT) is traded on NASDAQ Exchange in USA. It is located in 9713 Key West Avenue, Rockville, MD, United States, 20850 and employs 143 people. MaxCyte is listed under Health Care Equipment & Supplies category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 374.46 M. MaxCyte conducts business under Health Care Equipment & Supplies sector and is part of Health Care industry. The entity has 105.48 M outstanding shares of which 3.24 M shares are now shorted by private and institutional investors with about 11.38 trading days to cover.
MaxCyte currently holds about 240.89 M in cash with (21.69 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.37.
Check MaxCyte Probability Of Bankruptcy
Ownership AllocationThe majority of MaxCyte outstanding shares are owned by institutional investors. These third-party entities are usually referred to as non-private investors looking to shop for positions in MaxCyte to benefit from reduced commissions. Consequently, institutional holders are subject to a different set of regulations than regular investors in MaxCyte. Please pay attention to any change in the institutional holdings of MaxCyte as this could imply that something significant has changed or is about to change at the company.
Check MaxCyte Ownership Details
MaxCyte Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Portolan Capital Management, Llc | 2024-06-30 | 1.7 M | |
| Swedbank Ab | 2024-09-30 | 1.6 M | |
| Arrowmark Colorado Holdings, Llc (arrowmark Partners) | 2024-09-30 | 1.4 M | |
| Chevy Chase Trust Holdings, Inc. | 2024-09-30 | 1.3 M | |
| Dimensional Fund Advisors, Inc. | 2024-09-30 | 1.2 M | |
| Ameriprise Financial Inc | 2024-06-30 | 1.1 M | |
| Northern Trust Corp | 2024-09-30 | 860.3 K | |
| Silvercrest Asset Management Group Llc | 2024-06-30 | 708.2 K | |
| Centerbook Partners Lp | 2024-09-30 | 585.1 K | |
| Morgan Stanley - Brokerage Accounts | 2024-06-30 | 9.3 M | |
| Cadian Capital Management Lp | 2024-09-30 | 8.2 M |
MaxCyte Historical Income Statement
MaxCyte Stock Against Markets
MaxCyte Corporate Management
| James Brady | Senior Support | Profile | |
| Stark Thompson | Consultant | Profile | |
| Jill Mayer | Senior Resources | Profile | |
| Cenk Sumen | Chief Officer | Profile | |
| Douglas Doerfler | President, Founder | Profile | |
| Jay Gelfman | Senior Operations | Profile |
Additional Tools for MaxCyte Stock Analysis
When running MaxCyte's price analysis, check to measure MaxCyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MaxCyte is operating at the current time. Most of MaxCyte's value examination focuses on studying past and present price action to predict the probability of MaxCyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MaxCyte's price. Additionally, you may evaluate how the addition of MaxCyte to your portfolios can decrease your overall portfolio volatility.